NASDAQ:DRMA Dermata Therapeutics Q3 2026 Earnings Date & Estimates $0.76 -0.01 (-1.43%) As of 03:11 PM Eastern This is a fair market value price provided by Massive. Learn more. Dermata Therapeutics is estimated to report Q3 2026 earnings on Wednesday, November 18, 2026. The conference call is scheduled for November 20, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 18, 2026Conference Call DateNovember 20, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Dermata Therapeutics in Q3 2026Dermata Therapeutics is expected to post earnings of -$0.55 per share on revenue of $25 thousand. In the same quarter a year earlier Dermata Therapeutics reported -$1.65 per share. Dermata Therapeutics last reported on August 11, 2026, posting -$0.74 per share and missing the -$0.55 consensus estimate. Dermata Therapeutics has beaten the consensus EPS estimate in 3 of its last 7 quarters.Consensus EstimatesConsensus EPS-$0.55Expected Revenue$25 thousandPrior-Year EPS-$1.65Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.74 (Missed by -$0.19)EPS Beat Rate3 of last 7 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Dermata Therapeutics Q3 2026 Earnings FAQ When does Dermata Therapeutics report Q3 2026 earnings? Dermata Therapeutics (NASDAQ:DRMA) is estimated to report Q3 2026 earnings on Wednesday, November 18, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Dermata Therapeutics' Q3 2026 earnings call? Dermata Therapeutics' Q3 2026 earnings conference call is scheduled for Friday, November 20, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Dermata Therapeutics? Analysts expect Dermata Therapeutics to post earnings of -$0.55 per share for Q3 2026. How much revenue is Dermata Therapeutics expected to report? The consensus revenue estimate for Dermata Therapeutics is $25 thousand for Q3 2026. Dermata Therapeutics Earnings HeadlinesDermata Therapeutics (NASDAQ:DRMA) Stock Falls 10.9% - Should You Sell?November 6, 2026 | americanbankingnews.comDermata Therapeutics: Dermata Advances Second Tome Skincare Product Toward Expected 2027 Launch with Initiation of Acne Clinical TrialOctober 29, 2026 | finanznachrichten.deExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December. The agenda at the upcoming G20 Summit in Miami has shifted, and new research points to a major monetary announcement from President Trump. A new documentary breaks down what this shift could mean for savings, investments, and the assets tied to it.November 10 at 1:00 AM | Porter & Company (Ad)Dermata Advances Second Tome Skincare Product Toward Expected 2027 Launch with Initiation of Acne Clinical TrialOctober 29, 2026 | finance.yahoo.comWhy is Dermata Therapeutics stock gaining Thursday?October 15, 2026 | msn.comBiotech Pre-Market Movers: DRMA, OPK Surge; BRNX, NIVF SlideOctober 15, 2026 | rttnews.comSee More Dermata Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Dermata Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dermata Therapeutics and other key companies, straight to your email. Email Address About Dermata TherapeuticsDermata Therapeutics (NASDAQ:DRMA) is a clinical-stage biotechnology company focused on developing treatments for dermatological diseases. The company’s research is centered on topical therapies intended to address common inflammatory and dermatologic conditions. Its lead product candidate, DMT310, is a once-weekly topical treatment being evaluated for conditions including psoriasis and acne vulgaris. The therapy is based on a proprietary platform derived from a naturally occurring freshwater sponge and is designed to deliver localized treatment to the skin. Dermata has also investigated additional applications of its platform for other dermatological disorders. Founded in 2014 and headquartered in San Diego, California, Dermata has conducted its clinical development activities primarily in the United States. The company became publicly traded on the Nasdaq exchange in 2021. Gerry Proeber has served as the company’s chief executive officer and chairman.View Dermata Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles D-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Microsoft’s Neocloud Pullback Isn’t a Crack in AI DemandOklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next? Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
